Cell Therapy Supply Chain

Perinatal stem cells don't fit neatly into multipotent or pluripotent categories.

Networks must standardize specimen collection before governance or data systems.

How accreditation bodies set the baseline standards cord blood banks must meet before release.

Federal rules require testing the birth mother instead of the newborn for perinatal tissue donors.

Contamination rates vary sharply by perinatal tissue type and demand separate facility zones.

Standard biobank software fails when tracking samples from two linked patients across one delivery.

Federal rules dictate which pathogens must be tested to clear perinatal tissue for clinical use.

Broken records from collection to use can destroy a perinatal sample's legal and clinical value.

Temperature control during transit determines whether cord blood stem cells survive for transplant.